Ovarian cancer is resistant to immune therapy. Because of this less than 15% will respond to treatments such as checkpoint inhibition or T Cell infusion which are effective as treatment for many other cancers.
Immune resistance occurs in ovarian cancer by various processes which include, downwards regulation of otherwise protective genes, and change of surface proteins on cancer cells that act as targets for immune response. This leads to platinum resistance and early recurrence.
Understanding of this altered immune status results in new classifications of cancer types,with separation of ovarian cancer into homologous recombination deficiency, (about 40%),and epithelial mesenchymal transition, (the rest). The latter group are the most immune resistant and have worse survival.
With this knowledge will come improved targeted therapy, probably in combination, looking to counter immune resistance and enable cytotoxic effect.
No comments:
Post a Comment